Breaking Canadian GLP-1 news
GLP-1 News — Page 5
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Find my best option
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Wegovy Titration Costs $2,160-$2,280 Before Maintenance Dose in Canada
Wegovy's 16-week titration to the 2.4 mg maintenance dose costs Canadian patients $2,160-$2,280 before they reach full-dose therapy, with no provincial coverage.
Health Canada 2026-27 Plan Ties Generic Approvals to Reimbursement
Health Canada's 2026-27 Departmental Plan names pharmaceutical affordability a key priority, aligning regulatory approval with reimbursement recommendations.
CBC Correction: Novo's Semaglutide Regulatory Exclusivity Ended January
CBC corrected its generic Ozempic report to clarify Novo Nordisk's regulatory exclusivity ended in January 2026, not the patent, which expired earlier.
Novo EVP Larsen Calls Savings Card 'Leading Tactic' in Canada
Novo Nordisk EVP Emil Kongshoj Larsen told investors the company's savings card is its 'leading tactic' against Canadian generic semaglutide competitors.
Pharmacy Cash Price Gaps: Costco Undercuts Rexall by Up to $90
A 2026 price guide shows Canadian pharmacies vary by $50–$100 monthly on semaglutide cash prices, with Costco lowest and Rexall highest among major chains.
CMA: Ontario Lists Ozempic as Limited Use; Alberta Requires Step Therapy
CMA explainer details how Ontario lists Ozempic as Limited Use and Alberta treats it as step therapy, while generic semaglutide substitution rules take shape.
Novo Nordisk Eyes Third Generic as 65% Price-Cut Trigger Looms
Novo Nordisk executive Emil Kongshøj Larsen says a third generic semaglutide entry in Canada will trigger a mandated 65% cut to Novo's list price.
Generic Semaglutide Hits Tier 2 Pricing: ~$114 Per 4-Week Supply
With two generic semaglutide approvals in Canada, pCPA tier rules cap the public-plan price at roughly $114 per four-week supply, skipping Tier 1 entirely.
Health Canada Advisory: Counterfeit GLP-1 Products Found in Canada
Health Canada warns consumers about unauthorized and counterfeit GLP-1 products sold by retailers and online, and is working with CBSA to block shipments.
Alberta Blue Cross: GLP-1 Plan Spend Won't Drop Despite Generics
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spend is unlikely to decline even as a semaglutide generic arrives mid-2026, citing broader uses.
CDA Pegs Mounjaro Public Coverage at $1.97B Over Three Years
Canada's Drug Agency estimates public plans would spend $1.97 billion on Mounjaro over three years, about $820 million more than current comparable drug spending.
Health Canada: Many Generics Run 45-90% Below Brand Prices
Health Canada says many generic medications cost 45 to 90 per cent less than brand-name versions, a benchmark now in focus after two semaglutide approvals.
BMO Analyst: Canada Is 'Test Case' for Generic GLP-1 Competition
BMO Capital Markets analyst Evan Seigerman says investors will watch Canada closely to see whether generic semaglutide can compete with branded peptides.
Gerstein: GLP-1s Are 'Powerful Drugs,' Not Supplements
Hamilton diabetes researcher Dr. Hertzel Gerstein cautions Canadians that semaglutide is a powerful drug, not a supplement, as the second generic clears Health Canada.
Sockalingam: Under 20% of Private Plans Cover Obesity Drugs
Obesity Canada's Dr. Sanjeev Sockalingam says fewer than 20% of Canadians with private drug plans can access approved obesity medications, citing $27.6B in 2023 costs.
Second Generic Semaglutide Cleared; 7 Submissions Still Pending
Health Canada authorized Apotex's generic semaglutide May 1, 2026, the second G7-first approval, with seven more generic submissions still under review.
Health Canada Queue: 7 Semaglutide Generics Await Decisions
After authorizing a second generic semaglutide on May 1, Health Canada says seven more submissions remain under review with decisions due in coming weeks.
Novo Nordisk Sees 'Low Single-Digit' Hit from Canadian Generics
Novo Nordisk executive Emil Kongshøj Larsen told analysts the company expects only a low single-digit impact from generic semaglutide entering Canada.
Experts Welcome Generic Semaglutide, Urge Caution on Reliance
McGill's Dr. Kaberi Dasgupta and Obesity Canada's Ian Patton react to Health Canada's G7-first generic semaglutide approvals, citing equity gains and public-health risks.
Obesity Canada: Generic Semaglutide Approval Should Reshape Coverage
Obesity Canada says Health Canada's generic semaglutide approvals should prompt governments and insurers to revisit coverage, citing under-20% private plan access.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada